COMPANY

Armata Pharmaceuticals

HQ: Los Angeles, CA source · armatapharma.com ↗ · West Coast

Keywords: bacterial infections Dental Caries Pseudomonas Aeruginosa Lung Infection Bacteremia Staphylococcus Aureus Staphylococcus Aureus Bacteremia Bacteremia Staph Bacteremia Due to Staphylococcus Aureus Non-cystic Fibrosis Bronchiectasis Cystic Fibrosis Pseudomonas Lung Infection Pseudomonal C16G2 AP-PA02 AP-SA02 C16G2 Varnish C16G2 Strip AB-SA01 AB-PA01 AB-SA01 (10^8 PFU per phage) AB-SA01 (10^9 PFU per phage)

Location: Los Angeles, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

13Trials (company is sponsor)

Timeline

Sep 23, 2026 Grant Government grant: $3.7M (total, as published), announced Sep 23, 2026. Source: SEC filing. source ↗
Jan 10, 2023 Trial start Phase 2: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection source ↗
Apr 26, 2022 Trial start Phase 1/Phase 2: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia source ↗
Dec 22, 2020 Trial start Phase 1/Phase 2: Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis source ↗
Jul 7, 2017 Trial start 2: A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects source ↗
Feb 9, 2017 Trial start Phase 2: A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application source ↗
Jan 27, 2017 Trial start Phase 2: A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects source ↗
2016-05 Trial start Phase 1: Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults source ↗
2015-11 Trial start 2: Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects source ↗
2015-07 Trial start Phase 2: Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects source ↗
2014-10 Trial start 2: Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses source ↗
2014-02 Trial start 2: Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults source ↗

Funding

Last 2 years.

Sep 23, 2026 Government grant: $3.7M (total, as published), announced Sep 23, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT05184764	Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia	Phase 1/Phase 2	Completed	Apr 26, 2022	Nov 7, 2024 (actual)
NCT05616221	Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection	Phase 2	Completed	Jan 10, 2023	Jul 17, 2024 (actual)
NCT04596319	Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis	Phase 1/Phase 2	Completed	Dec 22, 2020	Dec 14, 2022 (actual)
NCT03004365	A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects	Phase 2	Completed	Jan 27, 2017	Mar 29, 2017 (actual)
NCT03196219	A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects	2	Completed	Jul 7, 2017	Nov 22, 2017 (actual)
NCT03052842	A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application	Phase 2	Completed	Feb 9, 2017	Apr 5, 2017 (actual)
NCT02594254	Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects	2	Completed	2015-11	2016-06 (actual)
NCT02254993	Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses	2	Completed	2014-10	2015-06 (actual)
NCT02509845	Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects	Phase 2	Completed	2015-07	2016-02 (actual)
NCT02044081	Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults	2	Completed	2014-02	2014-07 (actual)
NCT03395769	Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic	Not listed	No longer available	Not listed	Not listed
NCT03395743	Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic	Not listed	No longer available	Not listed	Not listed
NCT02757755	Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults	Phase 1	Completed	2016-05	2016-08 (actual)